Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis

Overview of attention for article published in JCEM, February 2012

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

twitter: 2 X users

Readers on

mendeley: 60 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 13,973 followers.

RT @BiotechStockRsr: Vandetanib and rash http://t.co/RawVUV2Q $AZN $EXEL cabozantinib is a future competitor to vandetanib in MTC & appears to have less rash.

[VEGF] Risk of Rash in Cancer Patients Treated with Vandetanib: Systematic Review and Meta-Analysis.: Risk of... http://t.co/2SKjaBJq PM

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.